Table IV.

Association between BCL6, ZEB1 and ZEB2 protein expression an the clinicopathological characteristics of patients with breast cancer.

		BCL6 expression		ZEB1 expression		ZEB2 expression
Clinicopathological characteristic	Total no. of patients	n (%)	P-value	n (%)	P-value	n (%)	P-value
Age (years)
≤35	22	15 (68.2)	0.288	16 (72.7)	0.334	13 (59.1)	0.902
35–55	131	67 (51.1)		74 (56.5)		71 (54.2)
>55	75	43 (57.3)		46 (61.3)		42 (56.0)
Tumor size (cm)
≤2	19	5 (26.3)	0.019	6 (31.6)	0.02	4 (21.1)	0.007
2–5	164	91 (55.5)		99 (60.4)		95 (57.9)
>5	45	29 (64.4)		31 (68.9)		27 (60.0)
Lymph node metastasis
0	82	34 (41.5)	0.003	36 (43.9)	0.001	36 (43.9)	0.008
1–3	78	44 (56.4)		49 (62.9)		43 (55.1)
>3	68	47 (69.1)		51 (75.0)		47 (69.1)
Tumor grade
I	19	6 (31.6)	0.01	10 (52.6)	0.391	7 (36.8)	0.15
II	141	73 (51.8)		81 (57.4)		77 (54.6)
III	68	46 (67.6)		45 (66.2)		42 (61.8)
Tumor stage
I	9	1 (11.1)	0.001	1 (11.1)	0.001	1 (11.1)	0.001
II	110	49 (44.5)		51 (46.4)		49 (44.5)
III	98	67 (68.4)		75 (76.5)		68 (69.4)
IV	11	8 (72.7)		9 (81.8)		8 (72.7)
Estrogen receptor
−	136	78 (57.4)	0.351	83 (61.0)	0.605	81 (59.6)	0.113
+	92	47 (51.1)		53 (57.6)		45 (48.9)
Progesterone receptor
−	136	80 (58.8)	0.14	88 (64.7)	0.058	80 (58.8)	0.189
+	92	45 (48.9)		48 (52.2)		46 (50.0)
c-erbB-2
Low	148	73 (49.3)	0.023	82 (55.4)	0.076	74 (50.0)	0.03
High	80	52 (65.0)		54 (67.5)		52 (65.0)

BCL6, B-cell lymphoma 6; ZEB, zinc finger E-box-binding homeobox; c-erbB-2, erb-b2 receptor tyrosine kinase 2.